Literature DB >> 32480409

Dose-Response Relationships Between Gonadal Steroids and Bone, Body Composition, and Sexual Function in Aging Men.

Joel S Finkelstein1, Hang Lee2, Sherri-Ann M Burnett-Bowie1, Karin Darakananda1, Emily C Gentile1, David W Goldstein1, Sarah H Prizand1, Laura M Krivicich1, Alexander P Taylor1, Kendra E Wulczyn1, Benjamin Z Leder1, Elaine W Yu1.   

Abstract

CONTEXT: Most labs set the lower limit of normal for testosterone at the 2.5th percentile of values in young or age-matched men, an approach that does not consider the physiologic changes associated with various testosterone concentrations.
OBJECTIVE: To characterize the dose-response relationships between gonadal steroid concentrations and measures regulated by gonadal steroids in older men. DESIGN, PARTICIPANTS, AND INTERVENTION: 177 men aged 60 to 80 were randomly assigned to receive goserelin acetate plus either 0 (placebo), 1.25, 2.5, 5, or 10 grams of a 1% testosterone gel daily for 16 weeks or placebos for both medications (controls). PRIMARY OUTCOMES: Changes in serum C-telopeptide (CTX), total body fat by dual energy X-ray absorptiometry, and self-reported sexual desire.
RESULTS: Clear relationships between the testosterone dosage (or the resulting testosterone levels) and a variety of outcome measures were observed. Changes in serum CTX exceeded changes in the controls in men whose testosterone levels were 0 to 99, 100 to 199, 200 to 299, or 300 to 499 ng/dL, whereas increases in total body fat, subcutaneous fat, and thigh fat exceeded controls when testosterone levels were 0 to 99 or 100 to 199 ng/dL. Sexual desire and erectile function were indistinguishable from controls until testosterone levels were <100 ng/dL.
CONCLUSION: Changes in measures of bone resorption, body fat, and sexual function begin at a variety of testosterone concentrations with many outcome measures remaining stable until testosterone levels are well below the stated normal ranges. In light of this variation, novel approaches for establishing the normal range for testosterone are needed. © Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  aging; bone turnover markers; hypogonadism; testosterone

Mesh:

Substances:

Year:  2020        PMID: 32480409      PMCID: PMC7337183          DOI: 10.1210/clinem/dgaa318

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  26 in total

Review 1.  The International Index of Erectile Function (IIEF): a state-of-the-science review.

Authors:  R C Rosen; J C Cappelleri; N Gendrano
Journal:  Int J Impot Res       Date:  2002-08       Impact factor: 2.896

2.  Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging.

Authors:  S M Harman; E J Metter; J D Tobin; J Pearson; M R Blackman
Journal:  J Clin Endocrinol Metab       Date:  2001-02       Impact factor: 5.958

3.  Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men.

Authors:  J E Morley; F E Kaiser; H M Perry; P Patrick; P M Morley; P M Stauber; B Vellas; R N Baumgartner; P J Garry
Journal:  Metabolism       Date:  1997-04       Impact factor: 8.694

4.  Trends in serum lipids and lipoproteins of adults, 1960-2002.

Authors:  Margaret D Carroll; David A Lacher; Paul D Sorlie; James I Cleeman; David J Gordon; Michael Wolz; Scott M Grundy; Clifford L Johnson
Journal:  JAMA       Date:  2005-10-12       Impact factor: 56.272

5.  Harmonized Reference Ranges for Circulating Testosterone Levels in Men of Four Cohort Studies in the United States and Europe.

Authors:  Thomas G Travison; Hubert W Vesper; Eric Orwoll; Frederick Wu; Jean Marc Kaufman; Ying Wang; Bruno Lapauw; Tom Fiers; Alvin M Matsumoto; Shalender Bhasin
Journal:  J Clin Endocrinol Metab       Date:  2017-04-01       Impact factor: 5.958

6.  Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.

Authors:  Shalender Bhasin; Juan P Brito; Glenn R Cunningham; Frances J Hayes; Howard N Hodis; Alvin M Matsumoto; Peter J Snyder; Ronald S Swerdloff; Frederick C Wu; Maria A Yialamas
Journal:  J Clin Endocrinol Metab       Date:  2018-05-01       Impact factor: 5.958

7.  Age-specific population centiles for androgen status in men.

Authors:  D J Handelsman; B Yeap; L Flicker; S Martin; G A Wittert; Lam P Ly
Journal:  Eur J Endocrinol       Date:  2015-09-18       Impact factor: 6.664

8.  Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels.

Authors:  Rebecca Vigen; Colin I O'Donnell; Anna E Barón; Gary K Grunwald; Thomas M Maddox; Steven M Bradley; Al Barqawi; Glenn Woning; Margaret E Wierman; Mary E Plomondon; John S Rumsfeld; P Michael Ho
Journal:  JAMA       Date:  2013-11-06       Impact factor: 56.272

9.  Comparison of sex steroid measurements in men by immunoassay versus mass spectroscopy and relationships with cortical and trabecular volumetric bone mineral density.

Authors:  S Khosla; S Amin; R J Singh; E J Atkinson; L J Melton; B L Riggs
Journal:  Osteoporos Int       Date:  2008-03-13       Impact factor: 4.507

10.  Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men.

Authors:  William D Finkle; Sander Greenland; Gregory K Ridgeway; John L Adams; Melissa A Frasco; Michael B Cook; Joseph F Fraumeni; Robert N Hoover
Journal:  PLoS One       Date:  2014-01-29       Impact factor: 3.240

View more
  1 in total

Review 1.  Hypogonadism, Type-2 Diabetes Mellitus, and Bone Health: A Narrative Review.

Authors:  Vittoria Russo; Rui Chen; Reina Armamento-Villareal
Journal:  Front Endocrinol (Lausanne)       Date:  2021-01-18       Impact factor: 5.555

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.